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Novel treatments for multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis
(XDR-TB), or latent TB are needed urgently. Recently, we reported the formulation and characterization of the
nitroimidazo-oxazine PA-824 for efficient aerosol delivery as dry powder porous particles and the subsequent
disposition in guinea pigs after pulmonary administration. The objective of the present study was to evaluate
the effects of these PA-824 therapeutic aerosols on the extent of TB infection in the low-inoculum aerosol
infection guinea pig model. Four weeks after infection by the pulmonary route, animals received daily treat-
ment for 4 weeks of either a high or a low dose of PA-824 dry powder aerosol. Animals received PA-824
cyclodextrin/lecithin suspensions orally as positive controls, and those receiving placebo particles or no
treatment were negative controls. The lungs and spleens of animals receiving the high dose of inhaled PA-824
particles exhibited a lower degree of inflammation (indicated by wet tissue weights), bacterial burden, and
tissue damage (indicated by histopathology) than those of untreated or placebo animals. Treatment with oral
PA-824 cyclodextrin/lecithin suspension resulted in a more significant reduction in the bacterial burden of
lungs and spleen, consistent with a dose that was larger than inhaled doses (eight times the inhaled low dose
and four times the inhaled high dose). However, histopathological analysis revealed that the extent of tissue
damage was comparable in groups receiving the oral or either inhaled dose. The present studies indicate the
potential use of PA-824 dry powder aerosols in the treatment of TB.
Mortality rates attributed to tuberculosis (TB) worldwide
are increasing due to the epidemic of HIV coinfection and the
emergence of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) mycobacterial strains (20). There is an
urgent need for new therapies with (i) activity against MDR/
XDR and latent TB, (ii) shorter treatment duration, and (iii)
safe and effective use in HIV-infected TB patients. PA-824, a
leading compound in the 4-nitroimidazo-oxazine subclass, has
shown promise in all those areas, as demonstrated by efficacy
studies in the TB mouse model (11, 16–18, 24, 26). The mech-
anism of action of PA-824 appears to be the inhibition of the
synthesis of protein and cell wall lipid after activation by the
Mycobacterium tuberculosis F420 cofactor (13, 28). MIC values
of PA-824 against M. tuberculosis range from 0.015 to 0.25
g/ml for drug-sensitive strains and from 0.03 to 0.53 g/ml for
drug-resistant strains (9). In addition, this drug is active against
nonreplicating anaerobic M. tuberculosis.
Pharmacokinetic (PK) studies in rats and mice indicate that
when delivered by the oral route, PA-824 has excellent tissue
penetration (23); however, its pharmacokinetics appears to be
different when given to other species, including guinea pigs,
rabbits, and humans (19, 25). The disposition, safety, and tol-
erability of single and multiple escalating doses of PA-824 were
recently evaluated in two clinical studies with healthy volun-
teers (8, 9). After oral administration of tablets once daily,
maximal PA-824 plasma concentrations of 3 to 3.8 g/ml were
reached at 4 to 5 h and steady state was reached after 5 to 6
days, with an average half-life of 16 to 20 h, varying by dose
group. PA-824 appeared to be well tolerated with no effects on
vital signs, but adverse effects, including headache, stomach
discomfort, and clinically benign, reversible elevated serum
creatinine levels, were observed at higher doses in these clin-
ical studies (8, 9).
The goal of the work presented in this paper was to inves-
tigate the effectiveness of pulmonary administration of PA-824
in a low-dose infection guinea pig model of tuberculosis. PA-
824 exhibits sparing solubility and requires formulation in ex-
otic excipients for oral delivery at therapeutic doses. Local
delivery in the absence of these excipients to the site of treat-
ment would be beneficial pharmaceutically and therapeuti-
cally. Therefore, advantages of this approach might include
elimination of potential adverse effects and formulation addi-
tives used to increase solubility and oral bioavailability. This
would be achieved by delivering smaller total doses, with lim-
ited additives, directly to the primary site of infection, maxi-
mizing local concentrations while limiting systemic exposure.
The formulation and characterization of PA-824 in a dry
powder porous particle form for efficient aerosol delivery was
recently published (25). The disposition of PA-824 was deter-
mined after pulmonary administration of three escalating
doses of this powder to guinea pigs and compared to that after
intravenous (i.v.) and oral administration. Maximal PA-824
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plasma concentrations of 2 to 4.6 g/ml were reached 3 to 4 h
after administering the powders by inhalation. Significantly
longer half-lives and mean residence times were observed in
animals dosed by the pulmonary route than after oral or i.v.
administration. Moreover, while no PA-824 was detected in
lung fluid after oral or i.v. administration, sustained levels of
PA-824 were detected in the lung 32 h after pulmonary deliv-
ery of powders. Because of these encouraging findings, the
present pharmacodynamic studies were conducted in the
guinea pig model of TB to determine the efficacy of PA-824
powders delivered by the pulmonary route in the treatment of
TB. Prior to dosing, studies were performed to determine
aerodynamic properties of particles in a novel dosing chamber
to determine a dosing regimen for the efficacy study.
Efficacy studies with oral doses of PA-824 have been con-
ducted in guinea pigs (24) and mice (11, 16–18, 24, 26). The
guinea pig model of TB more closely resembles the progres-
sion and pathogenesis of the disease in humans and guinea pigs
can more readily be dosed by the pulmonary route with aerosol
than mice; hence, efficacy studies in this species are believed to
be more relevant to assessing the efficacy of PA-824 dry pow-
der aerosols for TB treatment.
MATERIALS AND METHODS
Materials. L-Leucine was obtained from Spectrum Chemicals & Laboratory
Products (Gardena, CA), and the phospholipid 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) was from Genzyme Pharmaceuticals (Cambridge, MA).
PA-824 was received from the Global Alliance for TB Drug Development (New
York, NY). Acetonitrile, ethanol USP grade, and methanol were purchased from
Pharmco Products Inc. (Brookfield, CT). Water from a Millipore Corp. (Bil-
lerica, MA) Milli-Q water purification system was used.
Manufacture of PA-824 and placebo particles. Respirable drug-containing and
placebo powders were prepared by spray drying. The PA-824 particles were
manufactured from a 70% ethanol solution at 55°C with 75% (wt/wt) PA-824,
20% (wt/wt) L-leucine, and 5% (wt/wt) DPPC, and the placebo was a 70%
ethanol solution containing 90% (wt/wt) L-leucine and 10% (wt/wt) DPPC. The
dry powders were prepared using a Niro Mobile Minor spray dryer (Columbia,
MD) with an inlet temperature of 107°C and feedstock flow rate of 60 ml/min, as
detailed elsewhere (25).
Characterization of dry powders. The spray-dried powders were characterized
in triplicate for particle size (volume and aerodynamic distributions), morphol-
ogy, and PA-824 content. The volume particle size distribution (volume median
diameter) of the spray-dried powder was measured by laser diffraction using a
HELOS system with a RODOS dry dispersing unit (Sympatec Inc., Law-
renceville, NJ) at an applied pressure of 200 kPa. The aerodynamic properties
and particle distribution of the powder (fine particle fraction [FPF] less than 5.8
m, mass median aerodynamic diameter [MMAD], and geometric standard
deviation [GSD]) were determined with standard methodologies by using an
eight-stage Andersen nonviable 1ACFM cascade impactor (ACI; Copley Scien-
tific Ltd., Nottingham, United Kingdom) and hand-held, breath-activated, cap-
sule-based dry powder inhaler device (Plastiape, Osnago, Italy). The morphology
of the dry particles was evaluated using a 982 field emission scanning electron
microscope (SEM; LEO, Carl Zeiss, Inc., Thornwood, NY) after coating powder
samples with a platinum/palladium layer (208HR sputter coater; Cressington
Scientific Instruments Inc., Watford, United Kingdom).
The PA-824 content of the spray-dried powder was determined by a reverse-
phase high-performance liquid chromatography (HPLC) method using an Agi-
lent Technologies 1100 series HPLC system (Palo Alto, CA). The mobile phase
was run on a linear gradient from 20% acetonitrile and 80% water to 60%
acetonitrile and 40% water over 30 min with 5 min of equilibration time. Analysis
was performed on a 50-l injection volume at a flow rate of 1.5 ml/min through
an Agilent Zorbax Eclipse XDB-C18 column (4.6 by 150 mm), and absorbance
was recorded at 330 nm. An Agilent Zorbax Eclipse XDB-C18 analytical guard
column was also used.
Respiratory infection. All animal procedures were approved by the University
of North Carolina Chapel Hill Institutional Animal Care and Use Committee.
Specific-pathogen-free male Dunkin-Hartley guinea pigs (Hilltop, Scottsdale,
PA) weighing 369  45 g were housed individually in a biosafety level 3 (BSL-3)
containment area with a 12-h light/dark cycle. Animals were allowed free access
to water and food at all times. Animals were infected via the respiratory route
with a small inoculum (2 105 CFU/ml) of M. tuberculosis strain H37Rv. Ani-
mals were placed randomly in an exposure chamber, and aerosols were gener-
ated by pumping compressed air through a modified MRE type 3 jet Collison
nebulizer (Waltham, MA) containing 5 ml of bacterial suspension. Validation of
this procedure indicated that it results in the inhalation and retention of 10 to 15
viable, virulent organisms per guinea pig (12, 27). Animals remained untreated
for 4 weeks following infection, when the bacterial burden is known to plateau
(14). Body weights of each animal were recorded throughout the study, as were
changes in behavior or any other signs of toxicity.
Determination of PA-824 inhaled dose. A custom-designed dry powder dosing
chamber (7) was used to deliver aerosol powders to the animals. The dosing
chamber was initially loaded in separate studies with two amounts of PA-824
powders, referred to as high (360 mg) and low (180 mg) nominal doses, in order
to achieve the actual dose inhaled by each animal. These initial loading doses of
powder were sufficient to deliver doses to the animal based on (i) efficiency of
delivery to the port of the dosing chamber and (ii) the proportion of this dose
inhaled by the animal. The doses delivered to the port were measured experi-
mentally, and the respirable dose was calculated. The efficiency of delivery to the
port of the dosing chamber from which the animal inhaled was approximately 6%
of the nominal doses (11.3 or 22.4 mg). The dose to the animal, derived from the
respirable dose (known as fine particle fraction, or proportion of dose at the
chamber port 3.2 m in rodents) was approximately 20% (low dose) or 28%
(high dose) (2.3 and 6.4 mg). Ultimately, measures of delivered dose were
obtained experimentally from analysis of plasma PA-824 concentrations, which
were assumed to reflect dose delivered to the lungs. Four healthy animals (no TB
infection) for each dose were placed in the ports of the dry powder dosing
chamber and allowed to inhale PA-824 aerosol. Particles were introduced into
the dosing chamber in designated quantities at 5-min intervals. Animals in the
high-dose group were exposed for 60 min, whereas animals in the low-dose group
were treated for 30 min.
Blood samples (0.35 ml) were collected after dispersion of the last portion of
particles in the chamber at 0, 0.08, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 h, and
plasma was separated and analyzed for PA-824 concentration as described pre-
viously (25).
Preparation of PA-824 suspension for oral delivery. In order to overcome the
poor solubility of PA-824, it was prepared in a cyclodextrin/lecithin formulation
as previously described (11, 24, 26). Briefly, a known amount of PA-824 was
added to 1 ml of a 10% solution of hydroxypropyl--cyclodextrin (Sigma-Aldrich,
Co., St. Louis, MO), and the mixture was stirred gently for 24 h at room
temperature (22 to 25°C). This suspension was then sonicated for 10 min (Sonic
Dismembrator probe; Fisher Scientific, Pittsburgh, PA). Frozen lecithin (Avanti
Polar Lipids, Inc., Alabaster, AL) was added while stirring at room temperature.
Lastly, the suspension was cooled in an ice bath and sonicated intermittently for
15 min to maintain the suspension temperature below 50°C.
Treatments. After infection was established, animals were randomly assigned
to five experimental groups that received the following treatments: inhaled PA-
824 particles at low and high doses loaded into the dosing chamber (180 and 360
mg, respectively), inhaled placebo particles (180 mg), oral PA-824 suspension (40
mg/kg), and the untreated controls. For treatment, the respective doses of PA-
824 and placebo particles were loaded at intervals into the dosing chamber and
administered to the animals by passive inhalation as described above. All animals
were treated daily for 4 weeks.
Necropsy. After 4 weeks of daily treatment (8 weeks after infection), animals
were sacrificed and necropsy was performed as follows. The chest and peritoneal
cavities were opened and the lungs, spleen, and liver were inspected to determine
the number of superficial lesions, and their wet weights were recorded. The
caudal left lung lobe and residual spleen tissue were placed in 10% neutral
buffered formalin for histopathological evaluation. For bacteriology, the caudal
right lung lobe and approximately three-quarters of the spleen tissue were ho-
mogenized separately using Teflon-glass homogenizers. The homogenates were
diluted with sterile saline, and aliquots for each tissue were inoculated onto
duplicate M7H10 agar plates (Hardy Diagnostics, Santa Maria, CA). The plates
were incubated at 37°C for 3 weeks. Visible CFU were counted, and data are
expressed as the base 10 logarithm (log).
Histopathology. Formalin-fixed lung and spleen tissues were trimmed, embed-
ded in paraffin wax, and sectioned at 5 m. For lungs, midsaggital sections were
taken from the right middle lobes. For spleens, a single cross-section was taken
for processing. The sections were mounted on glass slides, and microscopic
examinations were conducted with hematoxylin-eosin-stained slides from each
block. Microscopic examinations were conducted by a pathologist (Charles River
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Pathology Associates, Durham, NC) who was blinded with respect to the treat-
ment received by the animals.
Statistical analyses. Data were analyzed with the analysis of variance
(ANOVA) and least-squares significant differences multiple comparison
method. A probability level of 5% (P  0.05) was considered to be statistically
significant.
RESULTS
Particle manufacture and characterization. Drug-contain-
ing particles with a load of approximately 75% (wt/wt) PA-824
were prepared by spray drying. The resulting dry powder for-
mulation consisted of thin-walled porous particle structures.
The median volume diameter of the particles was 3.95  0.01
m, and the powder had desirable aerosol properties for hu-
man pulmonary delivery as indicated by an MMAD of 4.45 
0.10 m, GSD of 1.43  0.07, and FPF of 57.6  3.6%. The
PA-824 content of the powder was 75.7  0.7% of the total
mass as estimated by HPLC with UV detection.
Placebo particles had a similar thin-walled structure. The
median volume diameter of the particles was 6.48  0.03 m,
and the aerodynamic particle size distribution was character-
ized as follows: MMAD of 4.73  0.02 m, GSD of 1.52 
0.01, and FPF of 61.2  1.4%.
Determination of PA-824 inhaled dose. PA-824 plasma con-
centrations versus time curves are shown in Fig. 1. Considering
the upper limit in the MIC reported by Tyagi et al. (0.015 to
0.25 g/ml) (26) for drug-sensitive M. tuberculosis, including
the H37Rv strain used in the present study, animals inhaling
the low and high doses of PA-824 particles would have plasma
drug levels above the MIC for 5 h and 12 h, respectively,
whereas considering the lower MIC value, PA-824 plasma con-
centrations would be above the MIC for more than 24 h after
both doses.
The fraction of PA-824 powder delivered to the systemic
circulation by aerosol, which was calculated by the ratio of the
area under the time-concentation curve (AUC) after aerosol
administration versus the AUC after powder intratracheal in-
sufflation (25), was determined to be 6.7% for the low dose and
13.5% for the high dose. Thus, the estimated dose absorbed by
the animals receiving the low dose was 4.8 mg/kg and those
receiving the high dose was 9.7 mg/kg, as calculated using
the ratio of the AUC for aerosol and i.v. administration and
the bioavailability (25). It is worth noting that this absorbed
dose does not take into account drug that may have remained
in the airways, not absorbed, or absorbed in the lung tissue.
Efficacy studies. No significant changes in behavior or symp-
toms of toxicity were observed in the animals during the
4-week treatment period.
Wet tissue weight has been used as an indirect marker of
inflammation (2–4, 10, 15). In the present studies, wet lung and
spleen weights were used as indicators of the degree of inflam-
mation of each organ. Increased organ weights are indicative
of the extent of inflammation due to TB infection in that organ.
Figure 2 shows the organ weights corrected for body weight at
the time of necropsy. The wet lung weights of animals receiving
high and low doses of inhaled PA-824 particles were signifi-
cantly lower than those of untreated controls. The wet lung
weight in animals receiving the oral suspension of PA-824 was
significantly lower than that of untreated controls and animals
receiving placebo particles. There was no significant difference
between the lung weights in animals receiving inhaled and oral
treatments, suggesting a comparable effect of both formula-
tions on lung inflammation.
Likewise, the wet spleen weights in animals receiving either
oral or inhaled treatment were significantly lower than those in
untreated or placebo animals. There was no significant differ-
ence between the spleen weight in animals receiving inhaled
and oral treatments.
The number of viable bacteria per ml (CFU/ml) of organ
homogenate in lungs and spleens of animals receiving the
different daily treatments is shown in Fig. 3. Bacterial burden
in treated animals (inhaled and oral) was significantly lower
than in untreated and placebo controls. The number of bacte-
ria in the lungs of animals receiving 40 mg/kg of PA-824 sus-
pension orally was significantly lower (1.6  1.3 CFU/ml) than
FIG. 1. Plasma concentration versus time curves (log scale) after
passive inhalation of PA-824 particles in the dry powder dispersion
chamber.
FIG. 2. Lung and spleen wet weights of TB-infected guinea pigs
receiving the different treatments daily for 4 weeks (average 
standard deviation; n  6). ˆ, significantly lower than untreated
control (P  0.0048); #, significantly lower than untreated control
and placebo (P  0.001).
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all other groups (untreated, placebo, and PA-824 aerosol
treated; P  0.0001). As for the bacterial burden in the lungs
of animals receiving the inhaled treatments, those receiving the
high dose of PA-824 particles displayed a significantly lower
burden (3.4  0.4 CFU/ml; P  0.0084) than those in un-
treated animals (4.2  0.3 CFU/ml) and in those receiving
placebo particles (4.6  0.5 CFU/ml). However, the number of
bacteria in the lungs of animals receiving the low dose of
inhaled PA-824 particles (3.8  0.3 CFU/ml) was significantly
lower (P  0.0074) than in those receiving placebo particles
(4.6  0.5 CFU/ml).
Similarly, the number of bacteria in the spleens of animals
receiving 40 mg/kg of PA-824 suspension orally (2.0  1.6
CFU/ml) was significantly lower (P  0.0001) than for all other
groups (untreated, placebo, and PA-824 aerosol treated).
However, the spleens of animals receiving the high dose of
inhaled PA-824 showed lower bacterial burdens (4.1  0.4
CFU/ml) than any other treatment (P  0.0027) with the
exception of oral PA-824. Spleens of animals receiving the low
dose of inhaled PA-824 particles had a significantly lower bac-
terial burden (4.3  0.3 CFU/ml) than those of animals receiv-
ing placebo particles (5.0  0.5 CFU/ml) or untreated controls
(4.6  0.2 CFU/ml).
Histopathology. Tables 1 and 2 summarize the histopatho-
logical analysis in infected guinea pig tissues after the different
treatments. Levels of lung infection, as indicated by tissue
damage, were mostly comparable among groups receiving oral
and inhaled treatments (Table 1). The lungs of animals receiv-
ing oral or inhaled treatments had a significantly smaller pro-
portion of lung lobes (5%) affected by medium granulomas,
compared with more than 30% of lung lobes affected by me-
dium granulomas in animals receiving placebo particles or
untreated controls (Fig. 4). However, although fewer granulo-
mas were observed in treated animals, more of these exhibited
caseous necrosis than in the negative control group, in which
animals had more tissue involvement, presumably with higher
numbers of granulomas, but fewer exhibited caseous necrosis.
Histopathological evaluation of spleen tissues revealed that
only 5% of the white pulp (lymphoid tissue arranged around
the arteries of the spleen) was affected by tiny granulomas in
the spleens of animals receiving the high dose of inhaled PA-
824 particles and none of them exhibited caseous necrosis (Fig.
5B). Likewise, a smaller percentage of white pulp was affected
by small granulomas in the spleens of animals receiving the
oral PA-824 suspension (Fig. 5C), and some of these granulo-
mas exhibited minimal caseous necrosis. In contrast, untreated
animals and those treated with placebo particles had a high
percentage (60%) of white pulp affected by medium granu-
lomas (Table 2; Fig. 5D).
DISCUSSION
The aim of the present study was to evaluate the efficacy of
PA-824 dry powder aerosols in the treatment of TB. PA-824,
typically administered orally, demonstrates great promise in
treating both active and latent tuberculosis, with the potential
of treating MDR-TB. We postulated that by delivering drug-
containing powders directly to the lungs (i.e., the initial site of
TB infection and reactivation of the disease), high concentra-
tions could be achieved to treat the bacteria locally, thus min-
imizing systemic exposure.
We have recently shown the potential for PA-824 to be
formulated into a stable dry powder porous particle form for
delivery by the pulmonary route via simple dry powder inhalers
(25). The porous particle system is well suited for efficient
delivery to the lungs (1, 5, 6, 21). This high drug load formu-
lation has been shown to maintain physical, aerodynamic, and
chemical stability at room temperature for 6 months and under
refrigerated conditions for more than 1 year. This room tem-
perature stability may reduce the need for a cold chain for
storage and distribution, while short-term stability at elevated









Amt of necrosis in
affected granulomas
Placebo 30 Medium 10–30 Marked
Low dose 5 Medium 20–50 Mild/moderate
High dose 5 Medium/large 60–90 Mild/moderate
Oral 2 Medium 60–70 Mild
Untreated control 30–40 Medium 10–20 Moderate
a The percent affected is based on a visual estimate of the lung lobe without enumeration of the granulomas or measurements of the total parenchymal area.
FIG. 3. Number of viable bacteria (CFU/ml) at necropsy in lung
and spleen tissues of TB-infected guinea pigs receiving the different
treatments daily for 4 weeks (average  standard deviation; n  6). ,
significantly lower than any other group (P  0.0001); $, significantly
lower than low-dose group, untreated, control, or placebo (P 
0.0027); #, significantly lower than untreated control or placebo (P 
0.0084); * , significantly lower than placebo (P  0.0074).
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temperatures may allow for storage excursions under extreme
conditions.
Treatment with the different PA-824 formulations and
routes of administration (oral suspension and inhaled parti-
cles) appeared to be well tolerated by TB-infected animals,
based on observations of the animals during the period of the
study. Inhalation treatment with PA-824 particles appeared to
reduce manifestations of disease in the lungs and spleens of
guinea pigs. Animals receiving low and high doses of inhaled
PA-824 aerosols showed significantly less inflammation (as in-
dicated by wet tissue weights), a lower number of viable bac-
teria, and less tissue damage (as shown by histopathological
analysis) than untreated animals or those inhaling placebo
particles. Furthermore, bacterial burden appeared to be even
lower in the spleens of animals that inhaled the high dose of
PA-824 particles than in those that inhaled the low dose, and
tissue damage was observed to a lesser extent in those animals
as well. Notably, the percentage of white pulp affected by
granulomas in spleen of animals inhaling the high dose ap-
peared to be lower than that in animals receiving the oral
PA-824 suspension, as revealed by histopathology (Table 2;
Fig. 5), even though these orally treated animals exhibited
lower bacterial burdens in the spleen and lung.
The greater reductions in bacterial burden observed in the
lungs and spleens of animals receiving oral treatment are con-
sistent with the larger dose of 40 mg/kg, compared to the
delivered dose based on circulating concentrations after pow-
der inhalation of 4.8 (low) and 9.7 (high) mg/kg. Hence, it is
possible that these lower doses may not have resulted in
plasma levels of PA-824 above the MIC for a sufficient time to
have an enduring effect. It is also possible that the cyclodextrin/
lecithin suspension may have aided in the penetration of PA-
824 in tissues, thus contributing to the efficacy of the oral
treatment.
The efficacy of oral doses of PA-824 in the treatment of TB
has been previously evaluated in guinea pigs and mice as
monotherapy and in combination with other drugs. In the first
efficacy studies published by Stover et al. (24), a daily oral dose
of 100 mg/kg of PA-824 reduced the bacterial burden in the
lungs of guinea pigs by 1.5 logs and in mice by 3 logs. Tyagi et
al. (26) reported a 4-log reduction in the bacterial burden of
the lungs of mice after 8 weeks of daily 100-mg/kg doses of















Placebo 60–65 Medium Moderate Minimal 5–30
Low dose 40–50 Medium None NAb NA
High dose 0–5 Tiny None NA NA
Oral 0–60 Small Rare Minimal NA
Untreated control 30–80 Medium Occasional Minimal 20
a Each cross-section of spleen contained approximately 25 to 35 profiles of lymphoid white pulp, depending on the overall size of the spleen. The percent affected
is the estimated percentage of white pulp profiles that contained granulomas.
b NA, not applicable.
FIG. 4. Lung histopathology of infected guinea pigs receiving the
different treatments. Magnification, 4. (A) Low dose of inhaled PA-
824 particles; (B) high dose of inhaled PA-824 particles; (C) oral
suspension of PA-824; (D) untreated controls. Note the open airways
and smaller granulomas in panels B and C, contrasting with the large
surface of lung tissue affected with large granulomas in panel D.
FIG. 5. Spleen histopathology of infected guinea pigs receiving the
different treatments. Magnification, 10. (A) Low dose of inhaled
PA-824 particles; (B) high dose of inhaled PA-824 particles; (C) oral
suspension of PA-824; (D) untreated controls. Note the absence of
granulomas in panels B and C, contrasting with the large surface of
white pulp affected with large granulomas in panel D.
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PA-824, which had a comparable effect to that of 25 mg/kg of
isoniazid. At the same dose, Lenaerts et al. (11) achieved a
2-log reduction in lung bacterial burden after 2 weeks of treat-
ment, a 3.5-log reduction after 6 weeks, and a 4-log reduction
after 12 weeks of daily treatment. The difference in the results
obtained by Tyagi et al. (26) and Lanaerts et al. (11) may lie in
the M. tuberculosis strain employed to infect the mice. The
study by Tyagi et al. employed strain H37Rv, whereas Lanaerts
et al. employed the Erdman strain.
PA-824 appears to have greater efficacy in TB therapies
when employed in combination treatments. While 2 months of
treatment with PA-824 resulted in only a 2-log reduction in the
bacterial burden of the lungs of mice, a combination of ri-
fampin, pyrazinamide, and PA-824 decreased this bacterial
burden by 6 logs (16). Other studies (18) also showed that a
6-month treatment with moxifloxacin and PA-824 completely
sterilized the spleens of infected mice and that the combina-
tion of moxifloxaxin, pyrazinamide, and PA-824 cured mice
more rapidly than the combination of rifampin, isoniazid, and
pyrazinamide, shortening the treatment by at least 1 month
(17).
The reductions in bacterial burden observed in the lungs and
spleens of animals receiving oral treatment in the present study
are similar to those observed by Stover et al. (24) in guinea pigs
treated for 30 days, confirming the efficacy of oral PA-824 in
the relevant guinea pig model of TB. The reduction in bacterial
burden in the spleens of guinea pigs after oral treatment is
similar to that reported for mice infected with M. tuberculosis
Erdman strain after 2 weeks of treatment (11). However, in all
other mouse studies employing monotherapy, the reductions in
lung bacterial burdens have been greater (1 log) than the one
observed in the present study, which is likely to be the result of
longer treatment times (30 days) and different drug disposi-
tion in mice versus guinea pigs (16, 25).
The modest effect of inhaled PA-824 on bacterial burden in
the present study may be due to the magnitude of the dose
delivered to the animals (one-quarter and one-eighth of the
oral dose). The amount of PA-824 powder actually deposited
in the lungs of animals is limited by the physical characteristics
of the drug particles and by the efficiency of delivery, including
the length of time that an animal can be placed in the port of
the dosing chamber to inhale the powder and the cutoff diam-
eter in the nose of guinea pigs being significantly smaller than
that for humans (22). Nevertheless, these limitations may not
be an issue in patient therapy, considering the greater capacity
for powder delivery compared to guinea pigs. An appropriate
inhaler would be required to deliver therapeutic doses of pow-
der. The likelihood of success with the combination of inhaled
PA-824 therapy with another oral or inhaled drug(s) is good. In
order to take advantage of synergistic drug effects on TB bac-
teria it may be feasible to design an effective therapy consisting
of inhaled PA-824 with one or two more drugs, possibly moxi-
floxacin, which seems to have a better synergistic effect than
with pyrazinamide, ethambutol, or ethionamide (17, 18).
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